Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 7/20 | 0.44 |
| ▸ | NPC1 | O15118 | 6/20 | 0.44 |
| ▸ | PKM | P14618 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | ALPI | P09923 | 3/20 | 0.40 |
| ▸ | ALPG | P10696 | 3/20 | 0.40 |
| ▸ | ALPL | P05186 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15509199 | 0.80 | ALDH1A1 (0.53) | ALDH1A1RAB9ANPC1PKMSMN1; SMN2 | |
| SCHEMBL12233266 | 0.78 | TSHR (0.65) | TSHRALDH1A1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL1430587 | 0.78 | TSHR (0.50) | TSHRALDH1A1RAB9ANPC1KDM4E | |
| SCHEMBL25424983 | 0.77 | TSHR (0.49) | TSHRALDH1A1MAPTKDM4EL3MBTL1 | |
| SCHEMBL30107016 | 0.77 | TSHR (0.49) | TSHRALDH1A1MAPTKDM4EL3MBTL1 | |
| SCHEMBL20139853 | 0.77 | TSHR (0.49) | TSHRALDH1A1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL16427401 | 0.77 | TSHR (0.49) | TSHRALDH1A1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL21643603 | 0.77 | PDPK1 (0.60) | TSHRALDH1A1MAPTKDM4EL3MBTL1 | |
| SCHEMBL31386825 | 0.76 | TSHR (0.47) | TSHRALDH1A1RAB9ANPC1MAPT | |
| SCHEMBL6822905 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4051667-B1 | HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS | LILAC THERAPEUTICS INC (US) | 2026-01-28 | — | — | EP | disclosed |
| CN-114929676-B | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | 紫丁香疗法有限公司 | 2025-04-29 | — | — | CN | disclosed |
| US-12258354-B2 | AhR modulators | IDEAYA BIOSCIENCES, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| US-20250064787-A1 | Heterocyclic Carboxylate Compounds as Glycolate Oxidase Inhibitors | LILAC THERAPEUTICS INC (US) | 2025-02-27 | — | — | US | disclosed |
| WO-2024255697-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND MEDICAL USE THEREOF | 中国医药研究开发中心有限公司 | 2024-12-19 | — | — | WO | disclosed |
| US-12168002-B2 | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | Lilac Therapeutics, Inc. (US) | 2024-12-17 | — | — | US | disclosed |
| EP-4470538-A2 | HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS | Lilac Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| US-12150941-B2 | Process for preparing substituted pyrazolo[1,5-a]pyrazines | Sumitomo Pharma Co., Ltd. (JP) | 2024-11-26 | — | — | US | disclosed |
| EP-3719023-B1 | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZINONE DERIVATIVE AND MEDICAL USE THEREOF | SUMITOMO PHARMA CO LTD (JP) | 2024-10-16 | — | — | EP | disclosed |
| EP-3749669-B3 | AHR MODULATORS | IDEAYA BIOSCIENCES INC (US) | 2024-09-04 | — | — | EP | disclosed |
| EP-3004107-A1 | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | Janssen Pharmaceutica, N.V. (BE) | 2016-04-13 | — | — | EP | disclosed |
| US-20160022633-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | GILEAD SCIENCES, INC. | 2016-01-28 | — | — | US | disclosed |
| WO-2015155549-A1 | ANTIBACTERIAL COMPOUNDS | REDX PHARMA PLC (GB) | 2015-10-15 | — | — | WO | disclosed |
| US-9133210-B2 | Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis | GALAPAGOS NV (BE) | 2015-09-15 | — | — | US | disclosed |
| EP-2909212-A1 | SUBSTITUTED-1,4-DIHYDROPYRAZOLO[4,3-b]INDOLES | Takeda Pharmaceutical Company Limited (JP) | 2015-08-26 | — | — | EP | disclosed |
| US-20150225405-A1 | SUBSTITUTED-1,4-DIHYDROPYRAZOLO[4,3-b]INDOLES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-13 | — | — | US | disclosed |
| WO-2015018823-A1 | THIENO[2,3-C]PYRANS AS CFTR MODULATORS | GALAPAGOS NV (BE) | 2015-02-12 | — | — | WO | disclosed |
| US-20150045327-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | GILEAD SCIENCES, INC. | 2015-02-12 | — | — | US | disclosed |
| WO-2014195311-A1 | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-11 | — | — | WO | disclosed |
| WO-2014039831-A1 | SUBSTITUTED-1,4-DIHYDROPYRAZOLO[4,3-b]INDOLES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12150941-B2 | Process for preparing substituted pyrazolo[1,5-a]pyrazines | CYP3A5, CYP2F1, CYP4Z1 | TSHR 1940/4885ALDH1A1 232/4885RAB9A 398/4885 |
| US-12258354-B2 | AhR modulators | AHR, ARNT, RORB | TSHR 228/4885ALDH1A1 579/4885RAB9A 3199/4885 |
| US-20160022633-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, ABCB11, ABCC5 | TSHR 3441/4885ALDH1A1 506/4885RAB9A 807/4885 |
| US-12168002-B2 | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | UGDH, PGD, PNPO | TSHR 2776/4885ALDH1A1 184/4885RAB9A 4019/4885 |
| US-20150225405-A1 | SUBSTITUTED-1,4-DIHYDROPYRAZOLO[4,3-b]INDOLES | GPR119, RPLP2, FOXM1 | TSHR 2542/4885ALDH1A1 433/4885RAB9A 347/4885 |
| US-20250064787-A1 | Heterocyclic Carboxylate Compounds as Glycolate Oxidase Inhibitors | GLS, DUOX1, HAO1 | TSHR 3830/4885ALDH1A1 100/4885RAB9A 2679/4885 |
| US-20150045327-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, ABCB11, ABCC5 | TSHR 3441/4885ALDH1A1 506/4885RAB9A 807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.